Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease.
Am J Gastroenterol
; 2023 Oct 09.
Article
em En
| MEDLINE
| ID: mdl-37811776
ABSTRACT
INTRODUCTION:
Limited data exist evaluating antiobesity medications (AOM) in patients with inflammatory bowel disease (IBD).METHODS:
We performed a case-control study evaluating the effectiveness and safety of AOM in patients with IBD with obesity, matched to non-IBD controls.RESULTS:
After 12 months, the case (n = 36) and control (n = 36) groups achieved similar percent total body weight loss of -6.9 ± 8.3 and -8.1 ± 7.0 (P = 0.30), respectively. Side effect profiles were similar between groups. Seven patients experienced an IBD flare, all managed medically.DISCUSSION:
AOM use in patients with IBD demonstrated similar effectiveness and safety when compared with that observed in the non-IBD population.
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Observational_studies
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article